Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Behçet's Disease

Why Avoid Blood Thinners for Behçet's Clots?

At a Glance

Blood clots in Behçet's disease are caused by inflamed blood vessels, not thick blood. Doctors prescribe immunosuppressants to treat this underlying inflammation. Standard blood thinners are avoided because they can cause fatal bleeding if the disease has weakened blood vessels in the lungs.

In this answer

5 sections

01

How Behçet’s Blood Clots Are Different

02

Why Immunosuppressants Are the Standard of Care

03

The Danger of Blood Thinners in Behçet’s Disease

04

Are Blood Thinners Ever Used?

05

Self-Advocacy in the Emergency Room

If your doctor prescribed an immunosuppressant instead of a traditional blood thinner (anticoagulant) for a blood clot, it is because Behçet’s disease requires a very different approach [1]. In most people, blood clots are caused by “thick” or slow-moving blood, but Behçet’s blood clots are caused by severe inflammation of the blood vessel walls [2][3]. Immunosuppressants treat the root cause by calming this inflammation [1][4]. Furthermore, using standard blood thinners in Behçet’s disease can be dangerous because they increase the risk of severe, life-threatening bleeding if you have weakened, inflamed blood vessels in your lungs [5][6][7].

Important: If you are currently taking a blood thinner, never stop taking it abruptly without contacting your prescribing physician first, as this can cause severe complications [8].

How Behçet’s Blood Clots Are Different

In typical blood clots (like a standard Deep Vein Thrombosis or DVT), the blood itself becomes prone to clotting due to stasis (sitting still for too long) or a genetic tendency to form clots [9].

In Behçet’s disease, the immune system mistakenly attacks the lining of the blood vessels, causing vasculitis (blood vessel inflammation) [2][10]. This inflammation damages the smooth inner wall of the blood vessel, creating a rough, sticky surface. A blood clot then forms and sticks tightly directly to this damaged wall [2][11][12]. Because the underlying problem is the inflamed vessel wall—not the blood itself—thinning the blood does not stop the active disease process [9][13][14].

Why Immunosuppressants Are the Standard of Care

Major medical guidelines, including those from European medical societies (EULAR), prioritize immunosuppressive therapy for managing vascular Behçet’s disease [15][16][17].

  • Treating the Root Cause: Medications that suppress the immune system stop the attack on your blood vessels [1][18]. Your doctor will often use a fast-acting medication (like corticosteroids) to quickly control inflammation, paired with a long-term medication (like azathioprine or biologic drugs) to keep it under control [18][19].
  • Healing the Vessel: Once the inflammation cools down, the vessel wall can heal. This naturally prevents new clots from forming and allows your body to gradually dissolve the existing clot over time [1][4][20].

The Danger of Blood Thinners in Behçet’s Disease

The most critical reason doctors avoid blood thinners in Behçet’s disease is the risk of severe bleeding [8][21][22].

The severe inflammation that causes blood clots can also severely weaken the walls of your arteries, causing them to bulge outward. These weak, balloon-like bulges are called aneurysms [12][18]. Behçet’s disease frequently causes aneurysms in the pulmonary arteries (the blood vessels in the lungs) [12][17].

If a patient has a pulmonary aneurysm, taking a blood thinner is considered highly dangerous [5][7]. The thinned blood can cause the fragile aneurysm to rupture, leading to massive, life-threatening bleeding into the lungs, which is usually visible as coughing up blood (hemoptysis) [5][6].

Are Blood Thinners Ever Used?

In some specific cases, a doctor might prescribe a blood thinner alongside an immunosuppressant. This usually happens if:

  • A blood clot is exceptionally severe or in a highly dangerous location, such as the brain [1][5].
  • The patient has not responded adequately to immunosuppressants alone [23][24].

However, before prescribing a blood thinner, your doctor will usually order imaging (like a CT scan of your chest) to absolutely verify that you do not have any pulmonary aneurysms [5][7]. Even when used, the blood thinner is only a temporary supporting measure, while the immunosuppressant remains the primary treatment [1][8][17].

Self-Advocacy in the Emergency Room

Because Behçet’s disease is rare, an emergency room doctor might see a blood clot and immediately want to prescribe a standard blood thinner [5]. It is important to advocate for yourself:

  • Tell them you have vascular Behçet’s disease and ask them to consult with your rheumatologist or specialist before giving you anticoagulants.
  • Remind them of the risk of pulmonary artery aneurysms and that EULAR guidelines prioritize immunosuppressants over blood thinners [15][17].
  • Go to the ER immediately if you experience warning signs of an aneurysm bleeding, such as suddenly coughing up blood, unexplained shortness of breath, or sudden chest pain [18][5].

Common questions in this guide

Why are blood thinners dangerous for Behçet's disease?
Blood thinners can cause severe, life-threatening bleeding in people with Behçet's disease. The inflammation from the disease can cause weak, bulging blood vessels in the lungs, known as aneurysms, which can rupture if the blood is thinned.
How do immunosuppressants treat blood clots in Behçet's?
Immunosuppressants target the root cause of the clots by calming the severe inflammation in your blood vessel walls. Once the inflammation cools down, the vessel wall can heal, preventing new clots and allowing your body to naturally dissolve the existing clot over time.
Are blood thinners ever used for Behçet's blood clots?
Yes, in rare and specific cases, such as a clot in the brain or if immunosuppressants alone aren't working, a doctor may temporarily prescribe a blood thinner. However, they will typically order a CT scan of the chest first to ensure you do not have any dangerous aneurysms in your lungs.
What should I tell an ER doctor if I have a blood clot with Behçet's disease?
Inform the emergency room staff that you have vascular Behçet's disease and that major medical guidelines prioritize immunosuppressants over standard blood thinners. Ask them to immediately consult with your rheumatologist before giving you any anticoagulants to prevent dangerous bleeding complications.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Have I had a recent chest CT scan to verify that I do not have pulmonary artery aneurysms?
  2. 2.What fast-acting and long-term immunosuppressants will we use to calm the inflammation in my blood vessels?
  3. 3.If I go to the emergency room for clot-related pain, exactly how should I explain my condition to doctors who might want to immediately start standard blood thinners?
  4. 4.What specific symptoms, such as coughing up blood or sudden chest pain, mean I should go to the emergency room immediately?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Can Behçet's Disease Cause Blindness? Vision RisksCan You Have a Healthy Pregnancy with Behçet's Disease?Does Behçet's Disease Cause Severe Fatigue & Tiredness?Will Behçet's Disease Burn Out With Age?Neuro-Behçet's vs MS: How Doctors Tell Them ApartHow Often Do You Need Eye Exams with Behçet's Disease?How to Manage Anxiety With Behçet's Disease?How to Relieve Behçet's Mouth Ulcer PainIs Behçet's Disease Contagious? What You Need to KnowIs Behçet's Disease Hereditary? HLA-B51 Gene ExplainedIs Behçet's Disease More Severe in Young Men?What Doctors Treat Behçet's Disease?What Do ESR & CRP Tests Mean in Behçet's Disease?What Is the Best Diet for Behçet's Disease?What is the Difference Between Behçet's and Crohn's?What Is the Difference Between Behçet's and Herpes?What is the Life Expectancy with Behçet's Disease?What Is the Pathergy Test for Behçet's Disease?What Triggers a Behçet's Disease Flare-Up? Key Causes

References

References (24)
  1. 1

    Can anticoagulation therapy in cerebral venous thrombosis associated with Behçet's disease be stopped without relapse?

    Roriz M, Crassard I, Lechtman S, et al.

    Revue neurologique 2018; (174(3)):162-166 doi:10.1016/j.neurol.2017.06.021.

    PMID: 29523353
  2. 2

    Clinical characteristics and radiographic outcomes of vascular Behçet's disease involving the aorta or its major branches.

    Lee S, Kang S, Eun Y, et al.

    Clinical rheumatology 2022; (41(6)):1769-1777 doi:10.1007/s10067-021-06031-9.

    PMID: 35128590
  3. 3

    Vascular involvement in Behçet's disease: the immunopathological process.

    de Vargas RM, da Cruz MLN, Giarllarielli MPH, et al.

    Jornal vascular brasileiro 2021; (20()):e20200170 doi:10.1590/1677-5449.200170.

    PMID: 34267787
  4. 4

    Neutrophil-mediated Thrombosis and NETosis in Behçet's Disease: a Hypothesis.

    Batu ED

    Journal of Korean medical science 2020; (35(29)):e213 doi:10.3346/jkms.2020.35.e213.

    PMID: 32715666
  5. 5

    Recommendations for the management of the vascular involvement in Behçet's disease by the Japanese National Research Committee for Behçet's disease-secondary publication.

    Nagafuchi H, Kikuchi H, Ishibash H, et al.

    Modern rheumatology 2023; (34(1)):182-193 doi:10.1093/mr/road002.

    PMID: 36658731
  6. 6

    [Vascular manifestations of Behcet's disease].

    Tazi Mezalek Z, Khibri H, El Fari S, et al.

    La Revue de medecine interne 2023; (44(2)):72-78 doi:10.1016/j.revmed.2022.11.011.

    PMID: 36564248
  7. 7

    Is Immunosuppressive and Thrombolytic Therapy Really Effective in a Patient With Intracardiac Thrombosis and Pulmonary Artery Aneurysm due to Behçet's Disease?

    Aladağ Çiftdemir N, Gökalp S, Eren T

    Archives of rheumatology 2019; (34(4)):451-456 doi:10.5606/ArchRheumatol.2019.7169.

    PMID: 32010896
  8. 8

    Pulmonary embolism due to an intracardiac thrombosis in a patient affected by Behçet's disease: a case report.

    Ambrosino V, De Marco F, Valli G, et al.

    European heart journal. Case reports 2024; (8(9)):ytae467 doi:10.1093/ehjcr/ytae467.

    PMID: 39286733
  9. 9

    Behçet's disease: New insights into pathophysiology, clinical features and treatment options.

    Greco A, De Virgilio A, Ralli M, et al.

    Autoimmunity reviews 2018; (17(6)):567-575 doi:10.1016/j.autrev.2017.12.006.

    PMID: 29631062
  10. 10

    Management of Behcet's syndrome.

    Karadag O, Bolek EC

    Rheumatology (Oxford, England) 2020; (59(Suppl 3)):iii108-iii117 doi:10.1093/rheumatology/keaa086.

    PMID: 32348509
  11. 11

    The Clinical Features, Risk Factors, and Outcome of Aneurysmal Lesions in Behcet's Disease.

    Zhou J, Shi J, Liu J, et al.

    Journal of immunology research 2019; (2019()):9198506 doi:10.1155/2019/9198506.

    PMID: 31930152
  12. 12

    Vasculo-Behçet's disease with a giant pseudoaneurysm of superficial femoral artery: A case report.

    Al-Doud MA, Al-Nusairat AN, Al-Shanableh NM, et al.

    International journal of surgery case reports 2023; (109()):108534 doi:10.1016/j.ijscr.2023.108534.

    PMID: 37524014
  13. 13

    Mucocutaneous manifestations of Behçet's disease: Pathogenesis and management from perspectives of vasculitis.

    Kim D, Nakamura K, Kaneko F, et al.

    Frontiers in medicine 2022; (9()):987393 doi:10.3389/fmed.2022.987393.

    PMID: 36530905
  14. 14

    Behçet's disease physiopathology: a contemporary review.

    Zeidan MJ, Saadoun D, Garrido M, et al.

    Auto- immunity highlights 2016; (7(1)):4 doi:10.1007/s13317-016-0074-1.

    PMID: 26868128
  15. 15

    A missed Behçet's case presenting with spontaneous epidural hematoma.

    Karataş L, Mengi G, Özyemişçi-Taşkıran Ö

    European journal of rheumatology 2015; (2(4)):167-168 doi:10.5152/eurjrheum.2015.0011.

    PMID: 27708958
  16. 16

    Treatment of Behçet's Disease: An Algorithmic Multidisciplinary Approach.

    Alpsoy E, Leccese P, Emmi G, Ohno S

    Frontiers in medicine 2021; (8()):624795 doi:10.3389/fmed.2021.624795.

    PMID: 33996847
  17. 17

    Concurrent Pulmonary Artery Aneurysm, Pulmonary Thrombosis, and Intracardiac Thrombus in Behçet's Disease: A Case Report.

    Alagha OA, Abu ElQomboz AY, Alsarafandi SF

    Cureus 2023; (15(8)):e43993 doi:10.7759/cureus.43993.

    PMID: 37746357
  18. 18

    The Effectiveness of Infliximab in Treating Vascular Manifestations of Behçet's Disease: A Systematic Review and Meta-Analysis.

    Bennani A, Benmansour EK, Serraj K

    Mediterranean journal of rheumatology 2025; (36(4)):539-546 doi:10.31138/mjr.080325.tav.

    PMID: 41607598
  19. 19

    An adolescent case of extensive Behçet`s disease successfully treated with Infliximab.

    Isıyel E, Bakkaloğlu S, Oğuz D, et al.

    The Turkish journal of pediatrics 2019; (61(4)):585-588.

    PMID: 31990477
  20. 20

    Development of Pulmonary Artery Aneurysms Due to Behçet's Disease and Resolution after Treatment.

    Kage H, Goto Y, Amano Y, et al.

    Internal medicine (Tokyo, Japan) 2016; (55(22)):3337-3340 doi:10.2169/internalmedicine.55.6852.

    PMID: 27853079
  21. 21

    Case Report: Behçet's syndrome and venous thrombosis in children: a case study and review of the literature.

    Yin Q, Bian Y, Niu F, et al.

    Frontiers in immunology 2025; (16()):1664004 doi:10.3389/fimmu.2025.1664004.

    PMID: 41089700
  22. 22

    Bronchial Fissuring: A Severe Complication of Arterial Aneurysm.

    Thouil A, Rhazari M, Alaoui H, et al.

    Cureus 2023; (15(8)):e43029 doi:10.7759/cureus.43029.

    PMID: 37674955
  23. 23

    Anticoagulants and immunosuppressive therapy for thrombosis in Behçet's syndrome: a systematic review and meta-analysis.

    Chuklin A, Chiasakul T, Uaprasert N

    Journal of thrombosis and haemostasis : JTH 2025; (23(11)):3578-3589 doi:10.1016/j.jtha.2025.07.025.

    PMID: 40769432
  24. 24

    Chronic Budd-Chiari syndrome in Behçet's disease successfully managed with transjugular intrahepatic portosystemic shunt: a case report and literature review.

    Oblitas CM, Toledo-Samaniego N, Fernández-Yunquera A, et al.

    Clinical journal of gastroenterology 2020; (13(4)):572-578 doi:10.1007/s12328-020-01106-7.

    PMID: 32067188

This page is for informational purposes only and does not replace professional medical advice. Always consult your rheumatologist or prescribing physician before starting, stopping, or making changes to your Behçet's disease medications or blood thinners.

Get notified when new evidence is published on Behçet disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.